Sex Enrollment Gaps in Clinical Trials

What are sex enrollment gaps in clinical trials?

Sex enrollment gaps in clinical trials exist when one sex is enrolled in numbers that don't match how often that sex actually experiences the disease being studied. A 2025 analysis of FDA-approved drugs found that across trials submitted to the FDA between 2015 and 2023, women's enrollment frequently fell short of their share of the disease burden — meaning the data used to approve medicines often came disproportionately from men, even for conditions that affect women at higher rates.

That gap matters because sex shapes how a drug moves through the body, what side effects appear, and at what dose a medicine works. These are biological differences — in hormones, body composition, kidney clearance rates, and more — not lifestyle choices or preferences.

The evidence reveals specific patterns. A systematic review on hypertension and diabetes trials found that women and historically underserved populations were underrepresented in trials conducted at Federally Qualified Health Centers, even though those centers serve populations with high rates of both conditions. A PTSD trial analysis found that sex differences in enrollment patterns were predictable — researchers could model them in advance — which suggests the gaps aren't random accidents but structural features of how trials are designed. A cancer trial review identified specific recruitment barriers that kept underrepresented groups out of studies: scheduling conflicts, transportation obstacles, and eligibility criteria written so narrowly that they excluded people who would realistically use the drug.

Enrollment gaps don't mean a medicine is unsafe for women. They mean the trial did not establish how the medicine performs across the full range of people who will take it. A drug label that reports efficacy data drawn mostly from men in a given age range cannot tell you with confidence what to expect in a 58-year-old postmenopausal woman, a 32-year-old woman with an autoimmune condition, or anyone whose biology, life stage, or health history differs from the trial population.

Sex is biological. Gender, reproductive status, age, and life stage are distinct variables — and most trials have not tracked all of them carefully. Knowing which group was actually studied, and which wasn't, is the starting point for reading any peptide medicine's evidence base honestly.

This section is for general health education only and is not medical advice. Consult a licensed healthcare provider before making any decisions about medicines or treatments.

How large are the gaps in PTSD and psychiatric trials?

The sex enrollment gaps in PTSD and psychiatric trials are large, persistent, and poorly documented — meaning clinicians and researchers still lack reliable data on how these treatments perform specifically in women. A 2025 analysis of PTSD randomized clinical trials found that predicting which trials would enroll more women was difficult, and that enrollment patterns by sex were inconsistent across studies, leaving the evidence base uneven at best (PMID 42628151).

PTSD is diagnosed in women at roughly twice the rate seen in men. That disparity makes the enrollment gap especially consequential: when a condition disproportionately affects one group and the trials studying it don't reflect that, the resulting data can't answer the questions that matter most to that group's care.

Several specific problems stand out.

Enrollment doesn't match disease burden. Across FDA-approved drugs studied between 2015 and 2023, sex representation in trials frequently did not align with how heavily a condition fell on women versus men (PMID 42336860). Psychiatric conditions were no exception.

Subgroup reporting is inconsistent. Even when women in a study were enrolled, many trials did not report outcomes broken down by sex. A trial can include women and still tell us almost nothing about how women in that study responded differently — or whether they did at all.

Life stage is rarely tracked. Menstrual cycle phase, perimenopause, and postmenopause can all affect stress-hormone systems relevant to PTSD. The trials reviewed in PMID 42628151 did not systematically capture these variables, so the data can't answer whether hormonal life stage changes treatment response.

Underrepresentation compounds across identities. Trials studying hypertension and diabetes at Federally Qualified Health Centers showed that women from historically underserved populations faced compounded enrollment barriers (PMID 42465047). Psychiatric trials face the same structural problem, meaning the gap is wider for some women than aggregate numbers suggest.

When a label reports a psychiatric peptide or drug as effective, that finding may rest on a trial population that skewed male, skewed toward a narrow age range, or simply didn't analyze women in that study as a distinct group. The trial did not establish efficacy across the full range of people who carry a PTSD diagnosis.

This section is not medical advice. Speak with a qualified clinician about your specific situation before making any treatment decisions.

Are women underrepresented in rheumatoid arthritis and chronic disease trials?

Women are not underrepresented in rheumatoid arthritis trials the way they are in many other disease areas — but sex enrollment gaps in chronic disease research still shape what we know, and don't know, about how treatments work across different bodies. Rheumatoid arthritis affects women at roughly two to three times the rate it affects men, and trial enrollment has broadly reflected that skew. The gap shows up differently depending on the condition and the drug class being studied.

A 2024 FDA-approved drug analysis examined sex representation in trials relative to how much each disease actually burdens each sex. For some chronic disease categories, women in this study were enrolled at rates below their share of the disease burden — meaning the trial data skewed male even when women carry more of the illness. That mismatch matters because drug metabolism, immune response, and body composition can differ by biological sex, and a trial that underenrolls women produces thinner evidence for women.

For rheumatoid arthritis specifically, a 2025 meta-analysis of JAK inhibitor trials pulled individual patient data from randomized controlled trials and found that BMI influenced how well patients responded to this drug class. Women in this study made up a large share of the trial population, which is consistent with the disease's sex distribution. The analysis did not establish whether sex itself — separate from BMI or other factors — independently predicted response, and the authors did not report sex-stratified efficacy breakdowns as a primary outcome.

Enrollment numbers alone don't tell the full story. A systematic review on hypertension and diabetes trials found that even when women were enrolled in adequate numbers, results were rarely analyzed or reported by sex. Women in this study were present in the data but invisible in the conclusions. The same pattern appears across chronic disease research: presence in a trial does not guarantee that the findings apply equally to all participants.

A few concrete gaps worth knowing:

• Subgroup analyses by sex are inconsistently reported, so clinicians often cannot tell whether a drug's effect size differs between male and female patients.
• Age and reproductive status are rarely tracked as separate variables, so postmenopausal women and women of reproductive age are often grouped together in published results.
• Trial leadership also shapes research priorities: a 2024 review of oral and maxillofacial surgery trials found that women held a minority of principal investigator roles, a pattern seen across surgical and medical specialties that can influence which questions get asked.

The evidence base for rheumatoid arthritis peptide and biologic medicines is larger than for many other conditions, but "larger" does not mean complete. Ask your clinician what the trial label reports about the population studied — and whether sex-stratified data exist for the specific drug you are considering.

This section is for general health education only and is not medical advice. Speak with a qualified healthcare provider about your individual situation.

Which cancer trial strategies have actually improved enrollment of underrepresented groups?

Several cancer trial strategies have measurably closed sex enrollment gaps. The clearest evidence comes from sites that changed how they found, invited, and supported patients rather than simply hoping diverse groups would show up.

A 2025 review of "bright spots"—cancer centers that outperformed peers on enrollment of underrepresented groups—identified specific practices that worked, drawing on real site data rather than theory. PMID 42288829 The authors found that no single fix drove results. A cluster of structural changes acting together did.

The strategies with the strongest evidence from that review:

• Community navigation programs. Trained patient navigators—often from the same communities as potential participants—contacted eligible patients directly, explained trial options in plain language, and helped with scheduling. Sites with navigators enrolled more patients from underrepresented groups than those without.
• Broadening eligibility criteria. Many trials historically excluded patients based on comorbidities (other health conditions) that disproportionately affect certain populations. Sites that worked with sponsors to relax overly strict exclusion criteria opened trials to people who had previously been screened out before they could even decide whether to participate.
• Decentralized visits. Allowing some trial visits to happen closer to home—or via telehealth—reduced the transportation and time burden that falls unevenly across income levels, caregiving responsibilities, and geography.
• Language-concordant consent processes. Providing informed consent documents and study staff in a patient's preferred language increased both understanding and willingness to enroll.
• Institutional accountability metrics. Sites that tracked enrollment by race, ethnicity, and sex—and reported those numbers internally—were more likely to identify gaps and act on them.

A parallel finding from hypertension and diabetes trial research at Federally Qualified Health Centers (community clinics serving underinsured populations) showed that women were enrolled at rates closer to their share of disease burden when trials were conducted at those community sites rather than academic medical centers alone. PMID 42465047 Women in that study were not a uniform group; age, insurance status, and primary language all shaped who actually enrolled.

What the evidence does not yet show is which combination of strategies works best for peptide-specific trials, or how these findings translate across different cancer types, life stages, or sex-based biology. The bright-spots review focused on cancer broadly. The mechanisms driving enrollment gaps in peptide medicine trials may differ and remain understudied.

This section is for general health education only and is not medical advice. Speak with a qualified clinician about your specific situation.

What do sex enrollment gaps mean for patients reading drug evidence?

Sex enrollment gaps mean the drug evidence you're reading was often built on study populations that skewed male, leaving real questions about how a medicine behaves in women's bodies. That gap doesn't make a drug dangerous or useless — it means the data has limits you deserve to know about before you and your clinician make a decision.

A 2025 analysis of FDA-approved drugs found that sex representation in trials varied widely by disease area. Some conditions showed near-equal enrollment; others showed women significantly underrepresented relative to how often they actually carry that disease. When women are enrolled at lower rates than their share of the patient population, the trial's findings describe a group that doesn't fully reflect them.

Labels report what the trial found. They don't fill in what the trial didn't test. So when a label says a drug was studied in a mixed-sex population without breaking out results by sex, you can't tell whether women in that study responded the same way, at the same rate, or with the same side-effect profile as men. The trial did not establish those answers — the label simply can't give them.

Sex enrollment gaps can obscure several concrete things:

• Dosing signals. Body composition, hormonal environment, and kidney and liver function all affect how a drug moves through the body. Trials that don't analyze results by sex can miss differences in how much drug is needed or how long it stays active.
• Side-effect patterns. Research on PTSD trial enrollment found that sex differences in enrollment are predictable and systematic — meaning the gap isn't random noise, it's a structural feature of how trials get designed.
• Subgroup variation within women. Women are not one biology. Age, reproductive stage, and other health conditions all shift how a drug behaves. A trial that enrolls some women but doesn't report results by life stage tells you very little about a postmenopausal woman versus a woman in her thirties.

A systematic review of hypertension and diabetes trials found that women and historically underserved populations were underrepresented even in community health center research — settings specifically designed to reach diverse patients.

Reading drug evidence well means asking: who was actually in this study, and does that group resemble me? Your clinician can help you weigh what the data does and doesn't cover for your specific situation.

This content is for general health education only and is not medical advice. Talk with a qualified healthcare provider before making any decisions about medicines or treatments.